Kinetic Technologies Announces New IEEE® 802.3bt-Compliant Powered Device and DC-DC Flyback Controller Solution for PoE Power Supplies

15.11.2022 09:00:00 EET | Business Wire | Press release

Power management and video/audio interface IC leader Kinetic Technologies announced today the KTA1140 IEEE 802.3bt-compliant Powered Device Interface IC and the KTB1095 synchronous flyback control IC with integrated digital isolated feedback as the latest additions to their PoE and DC-DC Converter product lines.

Fully compliant with IEEE 802.3bt, 802.3at and 802.3af standards, the KTA1140 integrates input surge protection, a PD controller with 100V, low resistance 0.1Ω hot-swap MOSFET, which fully supports input power levels up to 90W. The PD controller also includes eight-event classification, ATDET, PD Detect, over temperature protection and under voltage lockout (UVLO). The KTA1140 is also designed to provide seamless support for local supplies down to 9.5V.

The KTB1095 is a highly integrated synchronous flyback converter with internal feedback utilizing a 3000VRMS digital isolator, designed to eliminate the need for an external opto-coupler, reducing cost and size. Operating over a wide operating voltage range from 5V to 100V, the KTB1095 includes both primary and secondary side, high current MOSFET drivers and employs current-mode constant on-time control for fast transient response. Featuring an adjustable soft-start function to limit start-up in-rush current, the KTB1095 also includes input voltage UVLO, output over-voltage-protection (OVP), cycle-by-cycle current limit, short-circuit protection and thermal shutdown.

“Our goal at Kinetic is to make it as easy as possible for our customers to design their power supplies,” said Erik Ogren, Kinetic Technologies’ Senior Director of Marketing. “The KTA1140 supports Class 8, 90W designs with its ultra-low resistance hot-swap MOSFET and simplifies system designs with local voltage support. KTB1095 takes advantage of Kinetic’s Tru-Iso™ technology to deliver integrated 3000V-rms on-chip digital isolator feedback, reducing BOM count and PCB area.”

KTA1140 and KTB1095 are sampling now, with production expected to begin in the first quarter of 2023.

Visit Kinetic Technologies for further information.

Key Product Highlights:

KTA1140 – PoE 802.3bt PD Interface

Fully supports IEEE® 802.3bt
- Input Power Levels Up to 90W
- Class 0-8 for PoE PD
Compatible with IEEE® 802.3af/at
IEC 61000-4-2/3/4/5/6 requirements for EMC
Seamless support for local power down to 9.5V
Programmable DC current limit
Low resistance (typ. 0.1Ω) Hot Swap MOSFET
5x5 mm, 20 lead QFN Package

KTB1095 – 100V Synchronous Flyback Controller with Digital Isolation

Wide 5V to 100V Operating Voltage Range
Integrated Digital Isolator Feedback
- 3000V-rms Integrated Isolation
±1% Voltage Reference
Integrated primary and secondary side MOSFET Drivers
- 3A Sink / 2A Source driving capability
Adjustable Switching Frequency from 100kHz to 700kHz
Integrated Protection: Cycle-by-cycle current limit, Input UVLO, OCP, SCP, TSP
SOIC-16 Wide Body (10.3mm x 7.5mm) Package

About Kinetic Technologies

Kinetic Technologies is a global designer, developer, and provider of proprietary and innovative high-performance analog and mixed-signal semiconductor products for a wide variety of markets. Kinetic’s products help its customers efficiently regulate power, intelligently protect their devices from harmful voltage and current spikes, and deliver high-bandwidth, low-latency, and secured connectivity for video, display, and general-purpose applications.

For more information, please visit http://www.kinet-ic.com/.

*Kinetic Technologies’ logo is a trademark of Kinetic Technologies. All other brand and product names appearing in this document are the property of their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005531/en/

Contact information

Robert Bendz
Phone: +1 -408-746-9000
Email: rbendz@kinet-ic.com

About Business Wire

Business Wire

http://www.businesswire.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom